AUSTIN, Texas, March 31, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the publication in Scientific Reports of a paper entitled "A Novel Proteomics Approach to Epigenetic Profiling of Circulating Nucleosomes".
Dr. Marielle Herzog, lead author of the paper and Volition's Research and Development Director, commented, "Our novel method detects and quantifies histone modifications present in the circulating nucleosomes in the blood of cancer patients. We believe that our work has highlighted for the first time that histone H2A1R3 citrulline is, in plasma, upregulated in colorectal cancer patients and so could be a biomarker we target for future Nu.Q® immunoassay development. Furthermore, the use of Nu.Q® Capture may open up the possibility of using mass spectrometry not only for biomarker discovery but also as a high throughput platform for screening and/or diagnostics. It is also very good to see that this Nu.Q® Capture assay was found to be robust, reproducible and easy to use in laboratories in both the U.S. and Europe. Finally, we are delighted that our report was published in such a good impact factor journal."
Commenting on the publication Cameron Reynolds, Chief Executive Officer of Volition, said, "Nu.Q® Capture is one of Volition's four key pillars and this publication is another very important step forward for the company. I am extremely pleased that we continue to be on the very cutting edge of epigenetics, and aim for Nu.Q® Capture to be an important enabling technology in the liquid biopsy space. We believe the Nu.Q® Capture technology will be useful not only when used in combination with mass spectrometry to discover new biomarkers as per this paper, but also as a DNA enrichment technology which could aid diagnosis, treatment selection and treatment/ disease monitoring when used in combination with either sequencing and/or our Nu.Q® assays."
Please download the Paper here
About Nu.Q® Capture and the Project
Nu.Q® Capture acts to isolate circulating nucleosomes from human plasma for further downstream proteomic and/or genomic analysis. The work published focused on mass spectrometry analysis.
Nu.Q® Capture enabled the quantification of histone modifications using less than 1ml of human plasma, and the analysis of the global alterations of histones Post-Translational Modifications (PTMs) associated with cancer.
The project exemplified that the combination of Nu.Q® Capture and mass spectrometry can be used for biomarker discovery and that this Nu.Q® Capture assay was robust, reproducible and easy to use in laboratories in both the U.S. and Europe.
The work was funded in part by the Walloon Region.
About Volition
Volition is a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Volition is primarily focused on human diagnostics but also has a subsidiary focused on animal diagnostics.
Volition's research and development activities are centered in Belgium, with a small laboratory in California and additional offices in Texas, London and Singapore, as the company focuses on bringing its diagnostic products to market.
For more information about Volition, visit Volition's website volition.com or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Media / Investor Contacts
Louise Batchelor, Volition +44 (0)7557 774620 |
Scott Powell, Volition investorrelations@volition.com +1 (646) 650 1351 |
Jen Lewis, Pegasus +44 (0)7809 867943 |
Joseph Green, Edison Advisors +1 (646) 653 7030 |
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to the effectiveness of Volition's blood-based diagnostic and prognostic tests and Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic or prognostic products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic or prognostic products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics market and its rapid technological change; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries.
View original content:http://www.prnewswire.com/news-releases/volitionrx-limited-announces-publication-of-significant-nuq-capture-mass-spectrometry-paper-301259398.html
